https://www.selleckchem.com/pr....oducts/dl-ap5-2-apv.
[BMB Reports 2022; 55(3) 125-135].Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation,
Beğen
Yorum Yap
Paylaş
